Antisense drug discovery: Can cell-free screens speed the process?

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 3, 1998, Pages 249-254

  Branch, Andrea D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RIBONUCLEASE H; RNA;

CELL FREE SYSTEM; CHEMICAL REACTION; PRIORITY JOURNAL; REVIEW; RNA BINDING; SEQUENCE ANALYSIS;

EID: 0031856978     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.249     Document Type: Review

References (13)

1. BRANCH, A.D. (1998). A good antisense molecule is hard to find. TIBS 23, 45-50.
2. CHEN, H., FERBEYRE, G., and CEDERGREN, R. (1997). Efficient hammerhead ribozyme and antisense RNA targeting in a slow ribosome Escherichia coli mutant. Nat. Biotech. 15, 432-435.
3. CIOFFI, C.L., GARAY, M., JOHNSTON, J.F., McGRAW, K., BOGGS, R.T., HRENIUK, D., and MONIA, B.P. (1997). Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of A-Raf and C-Raf in serum-induced proliferation. Mol. Pharmacol. 51, 383-389.
4. DREWS, J., and RYSER, S. (1997). The role of innovation in drug development. Nat. Biotech. 15, 1318-1319.
5. FLORES-AGUILAR, M., BESEN, G., VUONG, C., TATEBAYASHI, M., MUNGUIA, D., GANGAN, P., WILEY, C.A., and FREEMAN, W.R. (1997). Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J. Infect. Dis. 175, 1308-1316.
6. HO, S.P., BAO, Y., LESHER, T., MALHOTRA, R., MA, L.Y., FLUHARTY, S.J., and SAKAI, R.R. (1998). Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotech. 16, 59-63.
7. HO, S.P., BRTTTON, D.H., STONE, B.A., BEHRENS, D.L., LEFFET, L.M., HOBBS, F.W., MILLER, J.A., and TRAINOR, G.L. (1996). Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24, 1901-1907.
8. MILNER, N., MIR, K.U., and SOUTHERN, E.M. (1997). Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotech. 15, 537-541.
9. MONIA, B.P., JOHNSTON, J.F., GEIGER, T., MULLER, M., and FABBRO, D. (1996). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668-675.
10. MUCCIOLI, C., GOLDSTEIN, D.A., JOHNSON, D.W., FEREZ, J.E., MORA-DUARTE, J.F., SHEPPARD, J.D., MANSOUR, S.E., CHAN, C.K., PALESTINE, A.G., GRILLONE, L.R., and CHANDLER, J.W. (1998). Fomivirsen safety and efficacy in the treatment of CMV retinitis: Phase III, controlled, multicenter study comparing immediate versus delayed treatment. Abstract 770, Retrovirus and Opportunistic Infection Conference, Chicago.
11. ROZEN, R, EDERY, I., MEEROVITCH, K., DEVER, T.E., MERRICK, W.C., and SONENBERG, N. (1990). Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mol. Cell. Biol. 10, 1134-1144.
12. STEIN, C.A., and KRIEG, A.M. (1994). Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4, 67-69.
13. WAGNER, R.W., MATTEUCCI, M.D., GRANT, D., HUANG, T., and FROEHLER, B.C. (1996). Potent and selective inhibition of gene expression by an antisense hetanucleotide. Nat. Biotech. 14, 840-844.